Member Info for Tiger16

Its interesting how they have not even completed the most easy of tasks which is the confirmation statement , now why is this interesting as I believe this is due to a RT global and PPP to become one and re list as so .. now that would be one serious come back .. would it not ...

Dont give up hope guys , our wait will be rewarded ..CEO still here and as large as life .. good things coming .. feel it in my water ..

I by pure error posted on the CPAI board .. maybe , some of those invested here have seen the light , and the Moon has given them the energy to make some serious money ...

361 to sell and it wants all my shares .. no thanks ..

Let her fly yehhhhhhhhhhhhhhhhhhhhhhhhhh to the moon we go ...

I feel very sorry for all those rainbow chasers .. who sold out .. this is now re rating , big time .. in come the buys level 2

Affrim Totally agree .. this will be re listed very soon .. could happen anytime now . Those doom and gloom posts , ignore , the only news we act upon is regulated news , and that is a RNS .. end of .

The CEO still there and kicking ..

Genuine Mistake , I dont cross ramp , like most on here through out the day.. Again my apologies ..

CPAI .. is coming back ,so good luck all , and if one checks my history , I do have not posted on any other board .. genuine error ..

Apologies guys wrong board .. CPAi doing very well today . Good luck all ..

🚨 ImmuPharma (AIM:IMM) – A Potential Game-Changer in Autoimmune Disease

ImmuPharma is gaining serious traction, and here’s why the market is watching closely for imminent news that could re-rate the stock dramatically:

⸻

🔬 P140: A Blockbuster-in-Waiting

• What it is: P140 is a first-in-class peptide therapy with a unique mechanism of action, initially developed for Systemic Lupus Erythematosus (SLE)—a life-threatening autoimmune disease affecting over 5 million people worldwide.

• Why it matters: The treatment landscape for lupus remains severely underserved, with limited options and no cures. P140 could not only change the treatment paradigm for lupus, but potentially expand into multiple autoimmune indications like Crohn’s, rheumatoid arthritis, and others.

• Big Pharma Value: For a large pharmaceutical company, P140 could be worth hundreds of millions—if not over a billion dollars—over its lifecycle if licensed and successfully commercialized. Blockbuster autoimmune drugs like Humira and Dupixent generate $10B+ annually, highlighting the scale.

⸻

🌍 Market Opportunity:

• The global autoimmune disease therapeutics market is expected to grow from $75 billion in 2021 to over $150 billion by 2030.

• With precision diagnostics now part of the P140 platform (thanks to a 2025 preclinical breakthrough), ImmuPharma could offer targeted treatment with patient stratification—a gold standard Big Pharma looks for.

⸻

💥 Near-Term Catalyst:

• The company has been actively engaging with major pharma (e.g., recent participation in JP Morgan Biotech Showcase).

• Backed by new funding, ongoing discussions are said to be progressing.

• With all the pieces in place—science, strategy, and funding—a licensing or partnership deal could land anytime.

If and when that happens, the share price could re-rate significantly.

⸻

🧬 Impact Beyond the Market:

• For patients, P140 could mean a better quality of life, fewer side effects, and more effective treatment.

• For investors, this is a biotech story with real scientific validation and commercial potential.

⸻

Watch this space—IMM could be one RNS away from revaluation.

#IMM #Lupus #Biotech #P140 #PharmaDeal #Autoimmune #BreakthroughTherapy #StockWatch

🔬 ImmuPharma (AIM:IMM) – Poised for a Major Pharma Partnership?

ImmuPharma is making significant strides in the biotech arena, particularly with its flagship autoimmune therapy, P140. 

Key Developments:

• Breakthrough Research: In January 2025, ImmuPharma’s shares surged by 200% following groundbreaking preclinical findings on P140. These findings enhance diagnostic accuracy and patient selection for systemic lupus erythematosus (SLE) treatments, positioning P140 at the forefront of personalized medicine for autoimmune diseases. 

• Strategic Fundraising: In February 2025, the company secured £2.91 million through an oversubscribed equity offering, with significant backing from Lanstead Capital. This funding aims to advance the P140 platform and bolster ongoing discussions with large pharmaceutical entities regarding potential licensing agreements. 

• Industry Engagement: ImmuPharma’s management attended the JP Morgan Conference and Biotech Showcase in San Francisco in January 2025. These premier events provided opportunities to engage with global biopharma companies, emphasizing the company’s commitment to establishing strategic partnerships. 

Outlook:

While no formal deal has been announced, ImmuPharma’s recent scientific advancements, successful fundraising, and proactive industry engagement suggest a strong trajectory toward securing a partnership with a major pharmaceutical company.

Old Share Dog ( lol apologies for spelling new device )

Thank you kindly for your experienced advice , I have taken it on board and I appreciate your wise words Sir .

Many thanks ..

God bless

I am also very honest and dont try to be some one I am not .. hence Newbee , for me to buy into CPAI , I will have to sell here , as all my funds are tied up in Rock , and PPP ..

Also My research is appreciated worldwide like the MOON and The starts .. CPAI will come down before close , the best time to buy there is after the AGM , nothing happening until then .. see if I am wrong old chap ..

God bless

Old share dog , I will confess , you do have a good sense of Humor ... lol

No its been 8 weeks now since The data was confirmed .. unless Tim is a serious narcissist . diluted , pathological liar , with a absolute disregard for the laws of karma .. then news needs to land right about now with a deal worth billions ..

The news really could land anytime now .. the radio silence is for a reason .. no interviews , no RNS since March 14 th in reference to corporate news ...

anyone looking to buy is now , anyone looking to sell is not now .. That my take .. mu opinion ..

Well the constant posts , noise .. there is no company , this will not come back , no operations .. complete rubbish ..

No one knows what is happening in the back ground .. none of us ..

as long as the CEO is present , this is coming back with a bang ..

We all know guys news is now seriously pending .. it can fall anytime , just like the rain after the sun ..

we all chase rainbows , yet this one requires a little , and I mean a little more patients .. the ink is getting ready to sign .. I can feel it in my water .. this is not financial advice ..

May the gods bless you all ..

My thoughts exactly .. the drop is way over done here , I am thinking of taking a position right now ..

Hi Sharebel , interesting , can we see this gain traction again today .. what a drop .. or do you see this go down further ?

On a serious note today is Moon day read the link and I am not endorsing the attendance or the company that is providing the venue in reference to the Moon . As I know little about them . What I do know is the moon , full moon comes around after many years and is a blessing from the universe . Hence if we all prey to the moon tonight when it arrives full and ask for IMM share price to jump to the moon .. it will happen . I’ll be asking for Rock and ppp to come out of suspension wife’s the wife sends me on a one way trip to the moon lol ..

Could tomorrow be the day .. this radio silence is quite loud on the basis that something is happening in the background .. data , ground breaking may I add has not been confirmed by big pharmaceutical, so it’s now or never ..

Certainly is Gold girl .. lets hope we get that rocket RNS tomorrow